Tucson, AZ – According to filings with the U.S. Securities and Exchange Commission, Cairn Therapeutics is raising $7,285,575.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Diarmuid Boran played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cairn Therapeutics
Cairn Therapeutics mission is to help patients beat their cancer. While tremendous advances have been made in the fight against cancer over the last two decades, it has not been enough. Too many people, young and old, still lose their battle with cancer, and those who survive often experience debilitating side effects from the drugs used to treat them. Our passion to make a positive difference in this regard is embodied in CT-262, the first in a new class of DNA binding agents that has the potential to revolutionize the use of chemotherapy.

To learn more about Cairn Therapeutics, visit http://www.cairntherapeutics.com/

Contact:
Diarmuid Boran, Chief Executive Officer
913-954-7879

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved